Unseen Warriors: Cheri Ambrose and the Global Fight Against Male Breast Cancer

Originally published in EMPOWERMENTOR 101 Newsletter By: Lennard M. Goetze, Ed.D

Introduction:
In the vast world of cancer advocacy, few have dared to champion a cause so overlooked, so misunderstood, and so deeply stigmatized. Yet, from the shadows of silence and misdiagnosis emerged a fearless voice—Cheri Ambrose. With unwavering determination and boundless compassion, she has dedicated over a decade to shining a light on a rarely spoken truth: men get breast cancer too. As the founder and driving force behind the Male Breast Cancer Global Alliance, Cheri has transformed personal conviction into a worldwide movement of awareness, support, and lasting change.\

Champion of the Voiceless: A Legacy of Bold Compassion
Cheri Ambrose is not a breast cancer survivor herself, but her deep empathy and fierce sense of justice have propelled her to become one of the most important voices in male breast cancer advocacy today. Her story is one of resilience, advocacy, and most of all, humanitarianism. Since 2013, Cheri has committed herself to bringing a voice to those who were silenced by stigma, isolated by fear, or dismissed by systems rooted in bias.

What began as quiet outreach and a desire to fill an information void soon evolved into a full-fledged mission. As she met more men and families grappling with the confusion of a “women’s disease” diagnosis, Cheri saw the devastating effects of societal misunderstanding: late diagnoses, lack of access to clinical trials, emotional alienation, and a complete absence of male representation in public health discussions. For many of these men, Cheri became their first source of validation—and their fiercest advocate.

In 2014, recognizing the urgent need for a centralized resource and community, Cheri founded the Male Breast Cancer Coalition (MBCC), a first-of-its-kind virtual haven for male survivors, caregivers, medical professionals, and advocates. What started as a grassroots initiative quickly gained national attention. The coalition became a beacon for those living in silence, providing not only practical information but also human connection and hope.

By November 2021, the MBCC had grown into a global network, prompting the formation of the Male Breast Cancer Global Alliance (MBCGA). This evolution reflected both the rising number of voices joining the cause and the growing credibility of Cheri’s leadership in the medical and advocacy communities. MBCGA expanded its focus to include not just support, but also scientific collaboration, research advancement, and clinical inclusion. Under Cheri’s guidance, MBCGA now connects survivors, researchers, clinicians, and pharmaceutical leaders from around the world to revolutionize care for men with breast cancer.

Cheri’s humanitarian work doesn’t stop at awareness—it takes tangible form in systemic change. She has been a leading force in persuading pharmaceutical companies to include men in the labeling of breast cancer medications once thought suitable only for women. Through persistence and strategic partnerships, she has opened the door for men to be included in clinical trials, long denied to them due to outdated gender assumptions. Her work not only helps save lives—it rewrites the rules of inclusion in modern medicine.

Mentoring a Movement & Shaping the Next Generation of Advocates
More than an advocate, Cheri is a mentor and mobilizer. She has trained and developed hundreds of survivor representatives—men who now share their stories in hospitals, classrooms, government hearings, and international summits. These men, once voiceless, are now empowered leaders in their own right, thanks to Cheri’s vision and coaching. Their voices form a chorus that breaks through stigma, reshaping public understanding one conversation at a time.

NCBC Heart of Advocacy Award

In March of 2025, Cheri was awarded the Heart of Advocacy honor by the National Consortium of Breast Centers Conference (Image-L)  in Las Vegas, NV in recognition of her tireless work, . This prestigious award reflects not just her achievements, but the genuine passion and humanity she brings to every aspect of her mission.

Beyond advocacy, Cheri plays a critical role in the broader cancer awareness movement. As Co-Editor of the New York Cancer Resource Alliance (NYCRA), she contributes to and curates a variety of health and wellness publications including Prevention101.org, NYCRA News, Health Scan News, and First Responders Health Report. Her writing and editorial work amplify her mission, reaching a wide array of professionals, patients, and policy-makers with essential health information and survivor stories.

Cheri is also a graduate of the National Breast Cancer Coalition’s PROJECT LEAD program, and she continues to serve as a key presence at major health summits such as the National Comprehensive Cancer Network Summit, ASCO, SABCS, and the ABC Global Conference in Lisbon. At each of these platforms, she represents not only male breast cancer patients, but all those fighting for recognition and equality in healthcare.

Building a Global Network of Support
Under Cheri Ambrose's leadership, the MBCGA has cultivated a robust network of partnerships with organizations dedicated to providing comprehensive support for men diagnosed with breast cancer. These collaborations aim to address the multifaceted needs of patients, from emotional support to financial assistance.

Financial Assistance through The CARE Project
Recognizing the financial burdens that often accompany a cancer diagnosis, the MBCGA partners with The CARE Project, Inc., a nonprofit organization founded by a breast cancer survivor. The CARE Project's MEN 2 Program offers financial assistance to male breast cancer patients, covering essential expenses such as insurance co-pays, utilities, rent, groceries, fuel, and transportation to and from treatment. This support allows patients to focus on healing without the added stress of financial hardship. 

Educational Resources and Awareness Campaigns
To promote early detection and awareness, the MBCGA has developed multilingual Self-Exam Cards for Men, available in nine languages, including English, Spanish, French, Italian, Dutch, German, Portuguese, Hebrew, and Polish. These cards provide easy-to-follow diagrams and instructions, highlighting warning signs and risk factors specific to men. The initiative is supported by pharmaceutical companies such as Daiichi Sankyo, Inc., Lilly, and Pfizer.

The MBCGA collaborates with leading healthcare institutions to advance research and clinical trials focused on male breast cancer. By bringing together patients, researchers, clinicians, and oncologists, the alliance aims to improve treatment options and outcomes for men diagnosed with the disease. 

In its mission to provide holistic support, the MBCGA partners with organizations such as Imerman Angels, which offers one-on-one support to cancer patients and caregivers through a network of trained Mentor Angels. These mentors provide emotional support and guidance, helping patients navigate their cancer journey. Additionally, the alliance collaborates with Learn Look Locate, an organization dedicated to breast cancer education and support. Together, they work to increase awareness, provide educational resources, and connect patients with support networks. 

Conclusion:

Advertisement

Cheri Ambrose’s legacy is not defined by accolades or titles—it is defined by lives changed, silences broken, and injustices righted. In a world where the voices of the marginalized are often drowned out, she has become a force of amplification. Her compassion is bold. Her fight is personal. Her impact is global. She has stood up for those who were told they didn’t belong in the breast cancer narrative, and through her, they now have not only a place—but a platform. From living rooms to research labs, from local communities to international health councils, Cheri has made one thing clear: breast cancer doesn’t discriminate, and neither should we.

Cheri Ambrose is more than an advocate. She is a changemaker, a humanitarian, and a beacon of hope for those navigating the darkest moments of their lives. In giving a voice to the voiceless, she has forever changed the story of male breast cancer—for the better.

_________________________________________________________________________________

Sponsor

For more information about the MALE BREAST CANCER GLOBAL ALLIANCE PREDISPOSITION TESTING PROGRAM, contact us at: www.mbcglobalalliance.org or contact our hotline at: 516.522-0777

 --------------------------------------------------------------------------------------------------------------------------

THIS MESSAGE IS BROUGHT TO YOU BY THE MALE BREAST CANCER GLOBAL ALLIANCE

The Male Breast Cancer Global Alliance (MBCGA) is leading the charge in awareness, education, and support for men affected by this disease. This organization has built a worldwide network of survivors, advocates, researchers, and healthcare professionals working to shatter the stigma and silence surrounding male breast cancer. They’ve played a crucial role in pushing for more inclusive research, advancing public health messaging, and ensuring men have access to the resources they need. Through tireless advocacy and collaboration, MBCGA has helped get male breast cancer recognized in global cancer policy and has elevated the voices of countless survivors. Their data-driven campaigns and survivor-led storytelling have reached millions, and their partnership with Bard Diagnostics is all about scaling that impact through accessible genetic testing.

  --------------------------------------------------------------------------------------------------------------------------

RELATED RESOURCES

Under a dedicated partnership with the Male Breast Cancer Global Alliance, BARDDIAGNOSTICS established key programs including: EARLIER DETECTION, PREDISPOSITION GENE TESTING, FIGHT RECURRENCE, ACTIVE SURVEILLANCE AND THE 2ND OPINION SCAN. For the many MEN who seek a significantly improved lifestyle or an upgrade in personalized healthcare, getting better answers about your state of health is paramount and IT ALL STARTS WITH STATE OF THE ART DIAGNOSTICS. The visionary paradigm that makes up true personalized medical care involves the integration between modalities, a collaboration between specialists and an upgrade in their strategic approach and you'll find it all at BardDiagnostics. 

 --------------------------------------------------------------------------------------------------------------------------

UNCOVERED – Shedding Light on Male Breast Cancer
The first official newsletter from the Male Breast Cancer Global Alliance, launched in proud partnership with AngioMedical Media and the Integrative Cancer Resource Society. Rooted in the belief that education is power, UNCOVERED delivers essential news, scientific updates, and survivor stories to inform and inspire. Each issue is packed with the latest in male breast cancer research, treatment innovations, and advocacy efforts from around the globe. Whether you're a patient, caregiver, or medical professional, UNCOVERED is your trusted source for facts and forward-thinking perspectives. Join us in uncovering the truth—and empowering lives through knowledge. (visit our regularly updated Newsletter)

 --------------------------------------------------------------------------------------------------------------------------

The INTEGRATIVE CANCER RESOURCE SOCIETY is a self-funded (Linkedin Based) independent volunteer group of non-profit foundations/charities, researchers, educators, community leaders and survivors. Under the spirit of collaboration and partnership, we are joined to bring a new level of support to cancer patients, survivors and all those seeking current information about cancer care. We form a unique network of support for one another- while driven to help those who need additional resources, technical updates or empowerment on the road to recovery. ICRS uses the power of the "interweb" to reach a global audience and a network of resources beyond our local borders. We have engaged some of the most impressive minds, perspectives and resources and enjoyed the exchange of vital information that is useful to all. Thanks in part to digital collaboration, these "foreign" connections have always been a part of our cancer crusade, now joining us in what we call "BORDERLESS MEDICINE".

 --------------------------------------------------------------------------------------------------------------------------

In great support of a the global movement of NON-INVASIVE medicine, we proudly introduce the INTEGRATIVE HEALTH RESEARCH CENTER by AngioInnovation Research (501c3). This New York city-based diagnostic imaging validation lab is established to clinically identify the efficacy, performance and supportive claims set by non-invasive therapeutics and diagnostic solutions. Co-founded by Dr. Robert L. Bard, the IHRC offers a non-profit, non-commercialized testing option for health-related innovations who seek an independent and impartial reporting through single-case pilot studies or IRB-Based clinical trials. The IHRC employs credentialed medical professionals and specialists in clinical research whose experience contributes to the unique strategic approach of each test study. (Visit: the AngioInstitute website)

Dr. Robert Bard Appointed Chair of Clinical Diagnostics at MBCGA

MEDICAL DIAGNOSTIC TRAILBLAZER IS THE NEXT MUSCLE IN MALE BREAST CANCER ADVOCACY

5-24-2025 / New York, NY — In a groundbreaking move that signals a powerful step forward in the fight against male breast cancer, the Male Breast Cancer Global Alliance (MBCGA) has announced the appointment of Dr. Robert Bard as Committee Chair of Clinical Diagnostics. A visionary in medical imaging and an internationally recognized advocate for integrative cancer care, Dr. Bard brings decades of experience and innovation to a role designed to unify health professionals and elevate awareness around this often-overlooked disease.

Dr. Bard’s new role is not merely ceremonial—it marks the official launch of a clinical diagnostics branch within MBCGA. This division aims to centralize diagnostic expertise, standardize early detection methods, and serve as an educational hub for medical professionals worldwide. For MBCGA co-founder Cheri Ambrose, the appointment represents “the highest task”—entrusting a leader who can connect radiologists, oncologists, and integrative medicine experts in a cause that has lacked unified attention for too long.

FROM ADVOCACY TO ACTION: A RETROSPECTIVE
“Dr. Bard has always been a driving force behind male breast cancer advocacy,” said Ambrose. “But this is the first time we’ve had the opportunity to make a tangible, global impact together. His networks and experience make him the perfect figure to lead this mission.”

With an over 10-year partnership already established between Dr. Bard and Male Breast Cancer advocates, this appointment feels like a natural evolution. Bard has long been a prominent advocate for bringing underrepresented cancers into the spotlight, especially those affecting male populations. His leadership comes at a time when the push for equity in cancer diagnostics and treatment is gaining critical momentum.

Currently a fellow of both the American Society for Lasers in Medicine and Surgery and the American Institute of Ultrasound in Medicine, Dr. Bard also serves in advisory roles for several national organizations including the ‘Are You Dense?’ Foundation, F.A.C.E.S. (National Firefighters Against Cancers & Exposures), the Women’s Health Collaborative, and the American Breast Cancer Foundation. His involvement extends to the Executive Board of the New York Arthritis Foundation and leadership in the Integrative Health Research Center.

Beyond his clinical practice in Manhattan, Dr. Bard is the founder of the AngioFoundation, a nonprofit focused on advanced diagnostic imaging. Through this organization, he launched UNCOVERED, the official newsletter for male breast cancer. The publication is not only an advocacy tool—it’s a platform for education, legislative news, and medical breakthroughs. As of 2025, UNCOVERED will serve as MBCGA’s flagship communication vehicle, supported by the editorial expertise of the NY Cancer Resource Alliance.  “The new role allows me to bring in clinical voices that can make a real difference,” said Dr. Bard. “There’s tremendous value in collaborative medicine—oncologists, radiologists, and even functional medicine practitioners have a seat at this table.”

Dr. Bard’s vision is deeply international. With past speaking engagements in Amsterdam, Paris, Vienna, Stratford-upon-Avon, and upcoming roles in The Hague, Montreal, and Milan, he carries MBCGA’s mission across borders. His appointment underscores the alliance's global ambitions and the pressing need to break stigmas around male breast cancer in every culture.

WHERE IT ALL STARTED (archive news) By: IPHA News Editor FOR IMMEDIATE RELEASE April 30, 2019 | Brooklyn, NY FDNY Retired Members Association Champions Cancer Awareness for First Responders   In a powerful and emotional gathering focused on post-9/11 health challenges, the Retired Members Association of the FDNY (RMA) hosted a compelling cancer awareness event, drawing a packed audience of career firefighters and medical advocates. This initiative marked the official launch of the First Responders Cancer Resource Team, an RMA-driven effort committed to confronting the silent epidemic of cancer among first responders. The program spotlighted critical topics such as early detection, preventive strategies, and the life-saving importance of seeking a second medical opinion. Underscoring the urgency of the message, Dr. Robert Bard, leading oncological imaging specialist and head clinical advisor for the initiative, made a surprise appearance. In his address, Dr. Bard emphasized the long-term health repercussions faced by 9/11 first responders and reaffirmed his support for the RMA’s proactive health directive.  One of the event’s most stirring moments came from Ms. Cheri Ambrose, dedicated NYCRA First Responder volunteer and president of the Male Breast Cancer Global Alliance. A tireless public advocate for cancer education, Ms. Ambrose passionately addressed what she calls the “invisible barrier” in public health: denial. “Denial is the deadliest delay,” she stated, urging the audience to take charge of their health. She proudly embraced her role in inspiring the urgent tone behind the group’s rallying cry: “Get Checked Now!” This landmark event underscored the RMA’s unwavering commitment to protecting those who once protected us, by fostering education, dialogue, and timely intervention in the fight against occupational cancers. (See complete article + also see PR NEWSWIRE for complete press release).

A GLOBAL VISION FOR EARLY DETECTION
Looking ahead, Dr. Bard envisions MBCGA-certified scanning centers across the U.S. and eventually worldwide. These centers would not only perform male breast cancer screenings but also offer education to other radiology facilities through turnkey programs developed by his team.

“This initiative is scalable,” Bard said. “We’re working to create educational packages that allow other institutions to replicate our diagnostic model. Our goal is not just to treat, but to teach—because awareness is as powerful as any treatment.”

Dr. Bard’s new appointment marks a significant moment in the journey of male breast cancer awareness. His deep ties in both the clinical and advocacy communities promise to reshape the diagnostic landscape for men at risk. Together with MBCGA, Dr. Bard is setting a new global standard—one where no one is left unseen, unheard, or undiagnosed.

 

For more information about the MALE BREAST CANCER GLOBAL ALLIANCE PREDISPOSITION TESTING PROGRAM, contact us at: www.mbcglobalalliance.org or contact our hotline at: 516.522-0777

 --------------------------------------------------------------------------------------------------------------------------

 FOR IMMEDIATE RELEASE

Lennard Goetze Appointed National Cancer Community Outreach Director

May 5, 2025 – The Male Breast Cancer Global Alliance (MBCGA) proudly announces the appointment of Lennard Goetze as its new National Cancer Community Outreach Director. A veteran in executive fundraising, strategic partnerships, and public advocacy, Mr. Goetze brings more than 30 years of distinguished leadership to this growing mission.

Lennard's impressive career includes pivotal roles in nationwide cancer initiatives, including the Leukemia & Lymphoma Society, the 9/11 CancerScan Project, Firefighters Against Cancer Exposures, LI2DAY, the Are You Dense? Foundation and the New York Cancer Resource Alliance. His passion for advocacy is matched by a track record of building cross-sector alliances and mobilizing influential networks.

Leading MBCGA’s Vision for 2025 and Beyond: “Lennard’s work has always inspired me,” says Cheri Ambrose, President and CEO of MBCGA. “Our 2025 leadership team is a dynamic force of professionals and visionaries, and having Lennard on board marks a bold step forward. His ability to unite thought leaders and champion cause-driven action will bring fresh momentum to our mission.”

A Legacy of Networking and Action: Renowned for his expertise in alliance-building, Mr. Goetze has dedicated much of his career to connecting professionals across industries. His early outreach efforts in 2001 focused on supporting firefighters affected by post-9/11 toxic exposures—an experience that helped cement his lifelong commitment to cancer awareness and prevention. His mastery of modern communication platforms, including LinkedIn, has furthered his reputation as a sought-after connector and advocate in the cancer care community.

Fueling MBCGA’s 2025 Expansion- In his new role, Lennard is tasked with spearheading MBCGA’s next phase of growth, including strategic development of educational programs, publishing initiatives, research partnerships, and outreach alliances.

He joins forces with internationally acclaimed imaging expert Dr. Robert L. Bard, who recently unveiled a 10-year retrospective of his groundbreaking work in rare cancer diagnostics using advanced ultrasound technologies (TheCancerDetective.org). Lennard Goetze’s appointment also strengthens collaboration with MBCGA’s Cancer Advisory Committee, which includes some of the top distinguished professionals in cancer care.

The complete list of cancer advisors is available at www.mbcglobalalliance.org.

A Global Call to Action - As MBCGA enters a transformative era, its mission expands beyond borders. With Lennard leading outreach initiatives and a coalition of respected medical leaders driving research and education, the organization is launching a series of international collaborations to elevate male breast cancer awareness on a global stage. Central to this effort is a renewed focus on leveraging social media platforms and digital networks to break the silence, dispel the stigma, and engage the public with facts, faces, and survivor stories. MBCGA’s 2025 campaign underscores a clear message: male breast cancer is real, it is urgent, and together—with visibility and voices—we will bring change.

-------------------------------------------------------------------------------------------------------------------------

THIS MESSAGE IS BROUGHT TO YOU BY THE MALE BREAST CANCER GLOBAL ALLIANCE

The Male Breast Cancer Global Alliance (MBCGA) is leading the charge in awareness, education, and support for men affected by this disease. This organization has built a worldwide network of survivors, advocates, researchers, and healthcare professionals working to shatter the stigma and silence surrounding male breast cancer. They’ve played a crucial role in pushing for more inclusive research, advancing public health messaging, and ensuring men have access to the resources they need. Through tireless advocacy and collaboration, MBCGA has helped get male breast cancer recognized in global cancer policy and has elevated the voices of countless survivors. Their data-driven campaigns and survivor-led storytelling have reached millions, and their partnership with Bard Diagnostics is all about scaling that impact through accessible genetic testing.

  --------------------------------------------------------------------------------------------------------------------------

RELATED RESOURCES

Under a dedicated partnership with the Male Breast Cancer Global Alliance, BARDDIAGNOSTICS established key programs including: EARLIER DETECTION, PREDISPOSITION GENE TESTING, FIGHT RECURRENCE, ACTIVE SURVEILLANCE AND THE 2ND OPINION SCAN. For the many MEN who seek a significantly improved lifestyle or an upgrade in personalized healthcare, getting better answers about your state of health is paramount and IT ALL STARTS WITH STATE OF THE ART DIAGNOSTICS. The visionary paradigm that makes up true personalized medical care involves the integration between modalities, a collaboration between specialists and an upgrade in their strategic approach and you'll find it all at BardDiagnostics. 

 --------------------------------------------------------------------------------------------------------------------------

UNCOVERED – Shedding Light on Male Breast Cancer
The first official newsletter from the Male Breast Cancer Global Alliance, launched in proud partnership with AngioMedical Media and the Integrative Cancer Resource Society. Rooted in the belief that education is power, UNCOVERED delivers essential news, scientific updates, and survivor stories to inform and inspire. Each issue is packed with the latest in male breast cancer research, treatment innovations, and advocacy efforts from around the globe. Whether you're a patient, caregiver, or medical professional, UNCOVERED is your trusted source for facts and forward-thinking perspectives. Join us in uncovering the truth—and empowering lives through knowledge. (visit our regularly updated Newsletter)

 --------------------------------------------------------------------------------------------------------------------------

The INTEGRATIVE CANCER RESOURCE SOCIETY is a self-funded (Linkedin Based) independent volunteer group of non-profit foundations/charities, researchers, educators, community leaders and survivors. Under the spirit of collaboration and partnership, we are joined to bring a new level of support to cancer patients, survivors and all those seeking current information about cancer care. We form a unique network of support for one another- while driven to help those who need additional resources, technical updates or empowerment on the road to recovery. ICRS uses the power of the "interweb" to reach a global audience and a network of resources beyond our local borders. We have engaged some of the most impressive minds, perspectives and resources and enjoyed the exchange of vital information that is useful to all. Thanks in part to digital collaboration, these "foreign" connections have always been a part of our cancer crusade, now joining us in what we call "BORDERLESS MEDICINE".

 --------------------------------------------------------------------------------------------------------------------------

In great support of a the global movement of NON-INVASIVE medicine, we proudly introduce the INTEGRATIVE HEALTH RESEARCH CENTER by AngioInnovation Research (501c3). This New York city-based diagnostic imaging validation lab is established to clinically identify the efficacy, performance and supportive claims set by non-invasive therapeutics and diagnostic solutions. Co-founded by Dr. Robert L. Bard, the IHRC offers a non-profit, non-commercialized testing option for health-related innovations who seek an independent and impartial reporting through single-case pilot studies or IRB-Based clinical trials. The IHRC employs credentialed medical professionals and specialists in clinical research whose experience contributes to the unique strategic approach of each test study. (Visit: the AngioInstitute website)

Know Your Genes, Save Your Sons: The Truth About Male Breast Cancer and Genetic Risk

Yeah, you read that right. Breast cancer doesn't care if you have pecs instead of breasts. It's time to kill the myth: male breast cancer is real, dangerous, and often overlooked. But here’s what most men don’t know: this isn't just about you—it's about your kids. Your genes carry the story, and if you don’t know your predisposition, you might be passing down a deadly risk to your sons and daughters.

GENETIC RISK IS A FAMILY MATTER

Let’s cut to it. BRCA1 and BRCA2 mutations can hide in your DNA and silently stack the odds against you. These mutations don’t just increase your chances of breast cancer; they spike your risk for prostate and pancreatic cancers too. And if you carry them, there's a 50/50 chance your children do too.

This isn’t fear-mongering. It’s fact. Early detection through genetic predisposition testing can save lives—yours and theirs.

That’s where Bard Diagnostics comes in. In partnership with the Male Breast Cancer Global Alliance, we’re making noise about the quiet threat most men don’t even know they carry. We provide cutting-edge genetic testing that helps uncover hidden risks. It’s painless, fast, and it might be the most powerful health decision you ever make.

HERE’S THE HARD TRUTH

Every year, over 2,700 men in the U.S. are diagnosed with breast cancer. Around 530 of them die. That's more than one man a day. Think it won't happen to you? Think again. Male breast cancer might be rare compared to women, but when it hits, it often hits harder. Why? Because we don't talk about it. We ignore the signs. We delay the checkups. And sometimes, we don't even know it's a thing until it's too late.

 

KNOW THE RISKS

Here are some factors that can crank up your risk:

·        Age (most cases hit between 60 and 70)

·        A family history of breast cancer

·        Radiation exposure

·        Hormone therapy or conditions causing high estrogen levels

·        Liver disease

·        Obesity

·        Genetic mutations like BRCA1 and BRCA2

If you have a family history of breast, ovarian, or prostate cancer, this is your cue. Don’t just get checked for you—get checked for them. Your kids deserve to grow up with a dad who made smart choices.

GET AHEAD OF THE GAME WITH GENETIC TESTING

Genetic predisposition testing with Bard Diagnostics reveals if you're carrying BRCA or other high-risk mutations. It's simple. It’s confidential. It’s life-saving.

Don’t just wait for symptoms. That weird lump under your nipple, skin dimpling, or fluid leaking from your chest isn’t "nothing" just because you're a dude. If something feels off, it probably is.

WHAT YOU NEED TO WATCH FOR

Here are the signs that should have you picking up the phone:

·        A lump or swelling, usually painless

·        Skin irritation or dimpling

·        Nipple pain, redness, or inversion

·        Discharge from the nipple

·        Swollen lymph nodes under the arm

If you notice any of these, don’t brush them off. Don’t "wait and see." Don’t tough it out. That’s not brave. That’s reckless.

REAL STORIES, REAL MEN

This isn't just numbers. These are fathers, brothers, sons, and friends. The Male Breast Cancer Global Alliance has created a community of male survivors and advocates who prove that early detection saves lives. Their stories are proof that catching this early makes a huge difference.

 

THE BOTTOM LINE

Breast cancer doesn’t make you less of a man. Ignoring it might. Real strength is in prevention, in action, and in knowledge. Whether you’ve got a family history or you just want to be sure, getting tested is one of the smartest moves you can make.

So, here it is, plain and simple: check your chest, know your genes, and talk to your doctor. Then get in touch with Bard Diagnostics for testing that could change your life—and maybe your kids’ lives too.

This isn't just awareness. This is a wake-up call.

Be the guy who got checked. Not the one who wished he had.

For more information about the MALE BREAST CANCER GLOBAL ALLIANCE PREDISPOSITION TESTING PROGRAM, contact us at: www.mbcglobalalliance.org or contact our hotline at: 516.522-0777

“DROP THE BIAS” is the campaign and battle cry of the Male Breast Cancer Global Alliance—a bold call to end the harmful misconception that breast cancer is a “women-only” disease. This bias in medicine, media, and society creates dangerous blind spots in care, leaving men misdiagnosed, undertreated, or ignored. It limits access to screening, support, and survivor recognition. But bias also lives within—men often avoid seeking help out of fear, stigma, or shame. “DROP THE BIAS” confronts this cultural and clinical oversight head-on, urging the world to recognize that men get breast cancer too. The campaign is not just about awareness—it’s about action. By challenging outdated assumptions, educating providers, empowering survivors, and opening dialogue, the Alliance aims to rewrite the narrative and save lives. “DROP THE BIAS” is a mission, a movement, and a message to all: equity in cancer care starts with truth.

 --------------------------------------------------------------------------------------------------------------------------

THIS MESSAGE IS BROUGHT TO YOU BY THE MALE BREAST CANCER GLOBAL ALLIANCE

The Male Breast Cancer Global Alliance (MBCGA) is leading the charge in awareness, education, and support for men affected by this disease. This organization has built a worldwide network of survivors, advocates, researchers, and healthcare professionals working to shatter the stigma and silence surrounding male breast cancer. They’ve played a crucial role in pushing for more inclusive research, advancing public health messaging, and ensuring men have access to the resources they need. Through tireless advocacy and collaboration, MBCGA has helped get male breast cancer recognized in global cancer policy and has elevated the voices of countless survivors. Their data-driven campaigns and survivor-led storytelling have reached millions, and their partnership with Bard Diagnostics is all about scaling that impact through accessible genetic testing.

  --------------------------------------------------------------------------------------------------------------------------

RELATED RESOURCES

Under a dedicated partnership with the Male Breast Cancer Global Alliance, BARDDIAGNOSTICS established key programs including: EARLIER DETECTION, PREDISPOSITION GENE TESTING, FIGHT RECURRENCE, ACTIVE SURVEILLANCE AND THE 2ND OPINION SCAN. For the many MEN who seek a significantly improved lifestyle or an upgrade in personalized healthcare, getting better answers about your state of health is paramount and IT ALL STARTS WITH STATE OF THE ART DIAGNOSTICS. The visionary paradigm that makes up true personalized medical care involves the integration between modalities, a collaboration between specialists and an upgrade in their strategic approach and you'll find it all at BardDiagnostics. 

 --------------------------------------------------------------------------------------------------------------------------

UNCOVERED – Shedding Light on Male Breast Cancer
The first official newsletter from the Male Breast Cancer Global Alliance, launched in proud partnership with AngioMedical Media and the Integrative Cancer Resource Society. Rooted in the belief that education is power, UNCOVERED delivers essential news, scientific updates, and survivor stories to inform and inspire. Each issue is packed with the latest in male breast cancer research, treatment innovations, and advocacy efforts from around the globe. Whether you're a patient, caregiver, or medical professional, UNCOVERED is your trusted source for facts and forward-thinking perspectives. Join us in uncovering the truth—and empowering lives through knowledge. (visit our regularly updated Newsletter)

 --------------------------------------------------------------------------------------------------------------------------

The INTEGRATIVE CANCER RESOURCE SOCIETY is a self-funded (Linkedin Based) independent volunteer group of non-profit foundations/charities, researchers, educators, community leaders and survivors. Under the spirit of collaboration and partnership, we are joined to bring a new level of support to cancer patients, survivors and all those seeking current information about cancer care. We form a unique network of support for one another- while driven to help those who need additional resources, technical updates or empowerment on the road to recovery. ICRS uses the power of the "interweb" to reach a global audience and a network of resources beyond our local borders. We have engaged some of the most impressive minds, perspectives and resources and enjoyed the exchange of vital information that is useful to all. Thanks in part to digital collaboration, these "foreign" connections have always been a part of our cancer crusade, now joining us in what we call "BORDERLESS MEDICINE".

 --------------------------------------------------------------------------------------------------------------------------

In great support of a the global movement of NON-INVASIVE medicine, we proudly introduce the INTEGRATIVE HEALTH RESEARCH CENTER by AngioInnovation Research (501c3). This New York city-based diagnostic imaging validation lab is established to clinically identify the efficacy, performance and supportive claims set by non-invasive therapeutics and diagnostic solutions. Co-founded by Dr. Robert L. Bard, the IHRC offers a non-profit, non-commercialized testing option for health-related innovations who seek an independent and impartial reporting through single-case pilot studies or IRB-Based clinical trials. The IHRC employs credentialed medical professionals and specialists in clinical research whose experience contributes to the unique strategic approach of each test study. (Visit: the AngioInstitute website)

 

Pennsylvania's HB433 Advances: A Landmark Bill for Breast Health Equity Unanimously Passes the House

 By Lennard M. Goetze, Ed.D – AngioMedical News

 FOR IMMEDIATE RELEASE

In a significant step toward improving breast health care equity in Pennsylvania, House Bill 433 (HB433) passed the Pennsylvania House of Representatives with a resounding 198-5 vote on May 12, 2025. This pivotal legislation, aimed at expanding insurance coverage for diagnostic breast examinations without cost-sharing barriers, represents a victory for patients, advocates, and healthcare providers alike.

Background: The Need for HB433

The origins of HB433 trace back more than a year, when Cheri Ambrose, Founder and President of the Male Breast Cancer Global Alliance, reached out to the Pennsylvania Governor’s office and legislative stakeholders to advocate for improved access to breast imaging services — not just for women, but for all individuals, including men diagnosed with or at risk for breast cancer.

Historically, state insurance mandates have focused on screening mammograms, often leaving significant gaps in coverage for diagnostic follow-ups like MRIs, ultrasounds, and diagnostic mammograms when abnormalities are detected. This has led to financial strain and delayed diagnoses for many patients, particularly men with breast cancer, a group frequently overlooked in traditional breast health policy.

Recognizing this, the House Democratic Insurance Committee began work on HB433, designed to ensure that both screening and diagnostic breast imaging would be accessible without burdensome out-of-pocket costs — a move aligned with updated guidelines from the U.S. Health Resources & Services Administration (HRSA) and federal health insurance mandates set to take effect in 2026.

The Legislative Process: Stakeholder Collaboration and Amendment

On March 26, 2025, Joseph Keller, Senior Research Analyst for the House Democratic Insurance Committee, formally reached out to stakeholders for feedback on both the bill and a proposed amendment (A00204). This amendment refined HB433’s language to enhance its inclusivity and legal precision. Key changes included:

• Replacing gendered language: Substituting “women” with “individuals” to ensure breast health coverage for all, regardless of gender.

• Clarifying insurance applicability: Modernizing outdated legal references and definitions within Pennsylvania’s mammogram law.

• Defining covered costs: Clearly stating that “all costs” would include copayments, coinsurance, and deductibles — with exceptions for certain high-deductible health plans tied to Health Savings Accounts.

• Aligning with HRSA guidelines: Ensuring diagnostic breast examinations would include MRIs, ultrasounds, or diagnostic mammograms for any suspected abnormalities detected in initial screenings.

Cheri Ambrose remained an engaged advocate throughout the process, communicating regularly with Keller and other House staff to monitor progress. After a successful committee adoption of the amendment in April 2025, the bill was scheduled for a final House vote in May.

Final Passage and What Comes Next
On May 12, 2025, the Pennsylvania House of Representatives Led by House Speaker Rep. Joanna McClinton amended the historical act of May 17, 1921 (P.L.0682, No.0284), known as the "Insurance Company Law Of 1921. The house voted overwhelmingly in favor of HB433. Cheri Ambrose received confirmation of the vote directly from Joseph Keller, who expressed appreciation for the ongoing advocacy and stakeholder input that helped shape the bill’s passage. The bill now moves to the Pennsylvania Senate for further consideration. If approved there, it will proceed to the Governor’s desk for final enactment. “No one should have to go into debt to access the health care they need, but high out-of-pocket costs can discourage people from seeking care", states Rep. McClinton. By passing HB 433 this week, the state House took action to help more Pennsylvania men and women access diagnostic breast imaging which can save lives and reduce the overall costs to our state’s healthcare system.”

(L-Image) Representative Gina H. Curry - PA General Assembly also shared her statement about the recent historical legislative amendment. “Breast cancer does not discriminate, and neither should access to care. Men get breast cancer too, fathers, brothers, sons, yet many delay care due to stigma or cost. HB 433 ensures that if you find a lump, you can get answers no matter your gender, zip code, or bank account. Black and Hispanic women are more likely to be diagnosed at later stages and have higher mortality rates. Black women are 2.7 times more likely to face triple negative breast cancer and 28 percent more likely to die from it. This bill tears down the financial walls that keep people from getting the diagnostic tests they need. We are not just saving women’s lives, we are saving lives, period. Because cancer does not wait, and neither should we."

What This Means for the Public

For the public — particularly those affected by or at risk for breast cancer — HB433 represents a monumental step forward. Should it become law, Pennsylvanians will no longer face the burden of out-of-pocket costs for essential diagnostic breast exams if abnormalities are detected during initial screenings. This legislation ensures insurance plans offered, issued, or renewed in the Commonwealth will cover these vital services, aligning state law with evolving federal preventive care standards.

Importantly, by adopting gender-neutral language and including men within the framework of breast health care policy, HB433 acknowledges the realities faced by male breast cancer patients, a demographic long overshadowed in public health conversations.

Conclusion

HB433’s progress exemplifies the power of advocacy, stakeholder collaboration, and responsive legislation. As Pennsylvania moves one step closer to codifying these protections into law, advocates like Cheri Ambrose and legislative champions within the House Insurance Committee offer a clear reminder of what dedicated, patient-centered policy work can accomplish.

For more information about the MALE BREAST CANCER GLOBAL ALLIANCE PREDISPOSITION TESTING PROGRAM, contact us at: www.mbcglobalalliance.org or contact our hotline at: 516.522-0777

Hi Cheri- I wanted to thank you for what you've done in Pennsylvania for male breast cancer. This article echoes what I've been saying since my diagnosis. The BRCA gene mutation test has now been available for 25 years, but until my diagnosis, not one primary caregiver ever suggested I get the simple screening. This, in spite of their knowledge of the breast cancer devastation on my mom's side of the family. They ALL knew. If I was screened, I could have caught my cancer at Stage 1 or even Stage 0. But I was Stage 2 with about the most aggressive tumor one can have; a Ki67 score of 36!!  Nine out of 10 cousins on my mom's side of the family have tested positive for the BRCA2 mutation. Breast cancer took my grandmother, along with my mom and both of her sisters. One of my male cousins passed it on to his daughter. The BRCA2 mutation is "gender neutral," and the Pink Brigade ignores this, while men are passing the mutation to their daughters & sons! That's simple negligence. I'll be clean for 3 years this October 3, but I'm not "clear." The BRCA2 mutation is still there and can trigger new cancer in several places, like the liver & pancreas, the latter being a quick death sentence. So I continue to take daily adjuvants (tumor inhibitors) with all of the attendant side effects and keep my fingers crossed. Fortunately, I have new inhibitor meds my grandmother, mom & aunts never had. Please keep up your good work. I'm constantly beating the drum, too. I've been absent from the Facebook group, as there is a lot going on. But I'll make a point to get in there. I have updates to post on several drugs I'm on. All the best, Mark Larsen, Tampa Bay, FL

---------------------------------------------------------------------------------------------------------------------------------------------------

THIS MESSAGE IS BROUGHT TO YOU BY THE MALE BREAST CANCER GLOBAL ALLIANCE

The Male Breast Cancer Global Alliance (MBCGA) is leading the charge in awareness, education, and support for men affected by this disease. This organization has built a worldwide network of survivors, advocates, researchers, and healthcare professionals working to shatter the stigma and silence surrounding male breast cancer. They’ve played a crucial role in pushing for more inclusive research, advancing public health messaging, and ensuring men have access to the resources they need. Through tireless advocacy and collaboration, MBCGA has helped get male breast cancer recognized in global cancer policy and has elevated the voices of countless survivors. Their data-driven campaigns and survivor-led storytelling have reached millions, and their partnership with Bard Diagnostics is all about scaling that impact through accessible genetic testing.

 

RELATED RESOURCES

Under a dedicated partnership with the Male Breast Cancer Global Alliance, BARDDIAGNOSTICS established key programs including: EARLIER DETECTION, PREDISPOSITION GENE TESTING, FIGHT RECURRENCE, ACTIVE SURVEILLANCE AND THE 2ND OPINION SCAN. For the many MEN who seek a significantly improved lifestyle or an upgrade in personalized healthcare, getting better answers about your state of health is paramount and IT ALL STARTS WITH STATE OF THE ART DIAGNOSTICS. The visionary paradigm that makes up true personalized medical care involves the integration between modalities, a collaboration between specialists and an upgrade in their strategic approach and you'll find it all at BardDiagnostics. 

UNCOVERED – Shedding Light on Male Breast Cancer
The first official newsletter from the Male Breast Cancer Global Alliance, launched in proud partnership with AngioMedical Media and the Integrative Cancer Resource Society. Rooted in the belief that education is power, UNCOVERED delivers essential news, scientific updates, and survivor stories to inform and inspire. Each issue is packed with the latest in male breast cancer research, treatment innovations, and advocacy efforts from around the globe. Whether you're a patient, caregiver, or medical professional, UNCOVERED is your trusted source for facts and forward-thinking perspectives. Join us in uncovering the truth—and empowering lives through knowledge. (visit our regularly updated Newsletter)

The INTEGRATIVE CANCER RESOURCE SOCIETY is a self-funded (Linkedin Based) independent volunteer group of non-profit foundations/charities, researchers, educators, community leaders and survivors. Under the spirit of collaboration and partnership, we are joined to bring a new level of support to cancer patients, survivors and all those seeking current information about cancer care. We form a unique network of support for one another- while driven to help those who need additional resources, technical updates or empowerment on the road to recovery. ICRS uses the power of the "interweb" to reach a global audience and a network of resources beyond our local borders. We have engaged some of the most impressive minds, perspectives and resources and enjoyed the exchange of vital information that is useful to all. Thanks in part to digital collaboration, these "foreign" connections have always been a part of our cancer crusade, now joining us in what we call "BORDERLESS MEDICINE".

In great support of a the global movement of NON-INVASIVE medicine, we proudly introduce the INTEGRATIVE HEALTH RESEARCH CENTER by AngioInnovation Research (501c3). This New York city-based diagnostic imaging validation lab is established to clinically identify the efficacy, performance and supportive claims set by non-invasive therapeutics and diagnostic solutions. Co-founded by Dr. Robert L. Bard, the IHRC offers a non-profit, non-commercialized testing option for health-related innovations who seek an independent and impartial reporting through single-case pilot studies or IRB-Based clinical trials. The IHRC employs credentialed medical professionals and specialists in clinical research whose experience contributes to the unique strategic approach of each test study. (Visit: the AngioInstitute website)